Advertisement
Canadian Journal of Cardiology

Hearts on Fire: The Role of Inflammation in the Pathogenesis of Atherosclerotic Cardiovascular Disease and How We Can Tend to the Flames

  • Kevin E. Boczar
    Correspondence
    Corresponding author: Dr Kevin Boczar, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.Tel.: +1-613-696-7334; fax: +1-613-696-7247
    Affiliations
    Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

    School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
    Search for articles by this author
  • Rob Beanlands
    Affiliations
    Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

    Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Search for articles by this author
      Despite our best attempts to manage traditional cardiovascular (CV) risk factors with contemporary approaches, major adverse cardiac events continue to occur at high rates in patients with established atherosclerotic coronary artery disease (CAD). Inflammation is being increasingly recognized as a major driver, and potential treatment target, of the atherosclerotic disease process. Many physicians are now pondering the question of whether anti-inflammatory agents should enter their toolkit for treating patients with CAD. However, although great strides have been made in the area, more research is needed before anti-inflammatory medications become standard of care for patients with CAD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Tardif J.C.
        • Kouz S.
        • Waters D.D.
        • et al.
        Efficacy and safety of low-dose colchicine after myocardial infarction.
        N Engl J Med. 2019; 381: 2497-2505
        • Nidorf S.M.
        • Fiolet A.T.L.
        • Mosterd A.
        • et al.
        Colchicine in patients with chronic coronary disease.
        N Engl J Med. 2020; 383: 1838-1847
        • Hemkens L.G.
        • Ewald H.
        • Gloy V.L.
        • et al.
        Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis.
        Heart. 2016; 102: 590-596
        • Roubille C.
        • Richer V.
        • Starnino T.
        • et al.
        The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
        Ann Rheum Dis. 2015; 74: 480-489